Weaknesses In Gilead's Remdesivir Trial Designs Unlikely to Impact Approval Prospects In US

Urgency of the COVID-19 crisis, political pressure, and trends in FDA reviews all point in favor of Gilead, despite the company's decision to conduct open-label Phase III trials for remdesivir and only one study with a control arm.